Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTAFR | P25105 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251819 | 1.00 | NPSR1 (0.35) | NPSR1HPGDNPY1RNPY2RLMNA | |
| SCHEMBL252619 | 0.88 | LMNA (0.36) | NPSR1HPGDNPY1RNPY2RLMNA | |
| SCHEMBL252620 | 0.88 | LMNA (0.36) | NPSR1HPGDNPY1RNPY2RLMNA | |
| SCHEMBL251675 | 0.87 | HPGD (0.38) | NPSR1HPGDNPY1RNPY2RLMNA | |
| SCHEMBL251676 | 0.87 | HPGD (0.38) | NPSR1HPGDNPY1RNPY2RLMNA | |
| SCHEMBL252434 | 0.81 | LMNA (0.36) | NPSR1HPGDNPY1RNPY2RLMNA | |
| SCHEMBL252433 | 0.81 | LMNA (0.36) | NPSR1HPGDNPY1RNPY2RLMNA | |
| SCHEMBL17718345 | 0.77 | EGFR (0.42) | LMNATDP1USP2TSHRKMT2A | |
| SCHEMBL14870378 | 0.77 | EGFR (0.42) | LMNATDP1USP2TSHRKMT2A | |
| SCHEMBL4173841 | 0.74 | KMT2A (0.38) | LMNATDP1USP2TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2588468-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2588468-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2588468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2012003262-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003262-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | NPSR1 2664/4885HPGD 2211/4885NPY1R 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.